Industry
Biotechnology
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Loading...
Open
14.23
Mkt cap
603M
Volume
1.3M
High
14.63
P/E Ratio
-13.00
52-wk high
23.40
Low
13.19
Div yield
N/A
52-wk low
3.52
Portfolio Pulse from
December 07, 2024 | 10:30 am
Portfolio Pulse from
December 02, 2024 | 9:30 pm
Portfolio Pulse from
November 13, 2024 | 11:30 pm
Portfolio Pulse from
November 13, 2024 | 9:15 pm
Portfolio Pulse from
November 07, 2024 | 4:00 pm
Portfolio Pulse from
November 05, 2024 | 4:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 7:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.